- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Parkinson's drug wards off blindness in oldies
Washington D.C, Nov 15 (ANI): A team of researchers have discovered a drug, which is normally used to treat Parkinson's disease, that may be able to delay or prevent a common form of blindness among older people.
Researchers discovered a biological connection between darker pigmented eyes, which are known to be resistant to Age-related macular degeneration (AMD), and increased levels of a chemical called L-DOPA in those eyes. L-DOPA is frequently prescribed for Parkinson's patients.
They reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
Senior author Brian McKay of the University of Arizona said that rather than looking at what might cause AMD, they instead wondered why certain people were protected from AMD.
BrightFocus president Stacy Pagos Haller said that this exciting breakthrough showed the power of scientific discovery to give hope to millions of people across the nation and the world.
The study is published in the American Journal of Medicine. (ANI)
Researchers discovered a biological connection between darker pigmented eyes, which are known to be resistant to Age-related macular degeneration (AMD), and increased levels of a chemical called L-DOPA in those eyes. L-DOPA is frequently prescribed for Parkinson's patients.
They reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
Senior author Brian McKay of the University of Arizona said that rather than looking at what might cause AMD, they instead wondered why certain people were protected from AMD.
BrightFocus president Stacy Pagos Haller said that this exciting breakthrough showed the power of scientific discovery to give hope to millions of people across the nation and the world.
The study is published in the American Journal of Medicine. (ANI)
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751
Next Story